$800 Million is the total value of HealthCor Management, L.P.'s 59 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 43.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BSX | Sell | BOSTON SCIENTIFIC CORP | $37,127,000 | -44.9% | 958,600 | -47.0% | 4.64% | -31.4% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $31,807,000 | -9.2% | 62,980 | -7.7% | 3.98% | +12.9% |
| CNC | Sell | CENTENE CORP DEL | $23,418,000 | -48.8% | 300,970 | -44.4% | 2.93% | -36.3% |
| CI | Sell | CIGNA CORP NEW | $21,340,000 | -16.1% | 76,910 | -20.3% | 2.67% | +4.5% |
| CYTK | Sell | CYTOKINETICS INC | $21,054,000 | +10.4% | 434,560 | -10.5% | 2.63% | +37.4% |
| HUM | Sell | HUMANA INC | $20,824,000 | -5.8% | 42,920 | -9.1% | 2.60% | +17.2% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $20,648,000 | +16.2% | 859,240 | -6.9% | 2.58% | +44.6% |
| BIIB | Sell | BIOGEN INC | $18,677,000 | -77.9% | 69,950 | -83.1% | 2.34% | -72.4% |
| ANTM | Sell | ELEVANCE HEALTH INC | $17,674,000 | -32.5% | 38,910 | -28.3% | 2.21% | -16.0% |
| LIVN | Sell | LIVANOVA PLC | $16,654,000 | -45.2% | 328,030 | -32.6% | 2.08% | -31.8% |
| BMY | Sell | BRISTOL-MYERS SQUIBB CO | $15,864,000 | -50.0% | 223,150 | -45.9% | 1.98% | -37.8% |
| INCY | Sell | INCYTE CORP | $15,184,000 | -14.6% | 227,851 | -2.7% | 1.90% | +6.3% |
| HZNP | Sell | HORIZON THERAPEUTICS PUB L | $14,206,000 | -80.3% | 229,530 | -74.6% | 1.78% | -75.5% |
| ABT | Sell | ABBOTT LABS | $9,576,000 | -55.8% | 98,970 | -50.3% | 1.20% | -44.9% |
| HOLX | Sell | HOLOGIC INC | $8,861,000 | -68.2% | 137,330 | -65.8% | 1.11% | -60.4% |
| SGEN | Sell | SEAGEN INC | $7,846,000 | -57.0% | 57,340 | -44.4% | 0.98% | -46.5% |
| NTRA | Sell | NATERA INC | $2,854,000 | -91.0% | 65,130 | -92.8% | 0.36% | -88.8% |
| RVNC | Sell | REVANCE THERAPEUTICS INC | $1,744,000 | -91.1% | 64,590 | -95.4% | 0.22% | -88.9% |
| Sell | EQRX INC*w exp 12/17/202 | $29,000 | -64.2% | 35,239 | -64.8% | 0.00% | -50.0% | |
| LGVWS | Sell | LONGVIEW ACQUISITION CORP II*w exp 99/99/999 | $10,000 | -82.1% | 149,999 | -64.9% | 0.00% | -83.3% |
| MSACW | Sell | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $1,000 | -93.3% | 29,776 | -64.0% | 0.00% | -100.0% |
| OHPAW | Sell | ORION ACQUISITION CORP*w exp 02/19/202 | $0 | -100.0% | 50,105 | -63.5% | 0.00% | -100.0% |
| ITCI | Exit | INTRA-CELLULAR THERAPIES INC | $0 | – | -27,070 | -100.0% | -0.16% | – |
| PODD | Exit | INSULET CORP | $0 | – | -7,150 | -100.0% | -0.16% | – |
| ALGN | Exit | ALIGN TECHNOLOGY INCcall | $0 | – | -10,000 | -100.0% | -0.24% | – |
| CCXI | Exit | CHEMOCENTRYX INCcall | $0 | – | -100,000 | -100.0% | -0.25% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -239,820 | -100.0% | -0.26% | – |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -55,280 | -100.0% | -0.31% | – |
| QTRX | Exit | QUANTERIX CORP | $0 | – | -201,560 | -100.0% | -0.33% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $0 | – | -499,640 | -100.0% | -0.38% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -217,165 | -100.0% | -0.40% | – |
| XLV | Exit | SELECT SECTOR SPDR TRsbi healthcare | $0 | – | -34,610 | -100.0% | -0.45% | – |
| IBB | Exit | ISHARES TRishares biotech | $0 | – | -53,940 | -100.0% | -0.64% | – |
| ZBH | Exit | ZIMMER BIOMET HOLDINGS INC | $0 | – | -72,020 | -100.0% | -0.76% | – |
| COO | Exit | COOPER COS INC | $0 | – | -30,770 | -100.0% | -0.97% | – |
| UHS | Exit | UNIVERSAL HLTH SVCS INCcl b | $0 | – | -134,040 | -100.0% | -1.36% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -72,490 | -100.0% | -1.46% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORPcall | $0 | – | -500,000 | -100.0% | -1.87% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -1,097,370 | -100.0% | -2.73% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HCA HOLDINGS INC | 27 | Q1 2022 | 6.2% |
| ZIMMER HLDGS INC | 26 | Q2 2022 | 9.3% |
| DANAHER CORPORATION | 26 | Q3 2022 | 5.6% |
| NEUROCRINE BIOSCIENCES INC | 26 | Q4 2022 | 7.8% |
| UNITEDHEALTH GROUP INC | 24 | Q3 2022 | 6.4% |
| VERTEX PHARMACEUTICALS INC | 24 | Q3 2021 | 5.3% |
| HUMANA INC | 22 | Q3 2022 | 6.6% |
| BRISTOL-MYERS SQUIBB CO | 22 | Q3 2022 | 9.2% |
| BIOGEN INC | 21 | Q3 2022 | 8.5% |
| LABORATORY CORP AMER HLDGS | 20 | Q2 2020 | 8.3% |
View HealthCor Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CareView Communications Inc | May 26, 2023 | 186,970,000 | 32.0% |
| Research Alliance Corp. IISold out | February 14, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp IVSold out | February 14, 2022 | 0 | 0.0% |
| Aurinia Pharmaceuticals Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| MADRIGAL PHARMACEUTICALS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Medicus Sciences Acquisition Corp.Sold out | February 14, 2022 | 0 | 0.0% |
| Arcturus Therapeutics Holdings Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| Intersect ENT, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| NEVRO CORP | February 12, 2021 | 156,046 | 0.5% |
| ViewRay, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
View HealthCor Management, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-05-26 |
| 4 | 2023-05-26 |
| SC 13D/A | 2023-05-26 |
| 4 | 2023-04-04 |
| 4 | 2023-04-04 |
| SC 13D/A | 2023-04-03 |
| 13F-HR | 2023-02-15 |
| SC 13G/A | 2023-02-14 |
| 4 | 2023-01-04 |
| 4 | 2023-01-04 |
View HealthCor Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.